SURYAPHARM

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended March 31,2011.

Surya Pharmaceutical Limited has informed the Exchange that pursuant to the option exercised by investor regarding conversion of Share Warrants, the Board of Directors of the Company, in their meeting held on April 07, 2011 have allotted 1,00,00,000 fully paid Equity Shares on preferential basis to M/s Futuristics Garments Private Limited upon conversion of 10,00,000 Zero Coupon Convertible Share warrants. The total Share Capital after conversion stands at Rs. 20,27,52,380/- divided into 20,27,52,380 fully paid Equity Shares of Re. 1.00 each.

Surya Pharmaceutical Limited has informed the Exchange that pursuant to the option exercised by investor regarding conversion of Share Warrants, the Board of Directors of the Company, in their meeting held on March 31, 2011 have allotted 95,00,000 fully paid Equity Shares on preferential basis to M/s Futuristics Garments Private Limited upon conversion of 9,50,000 Zero Coupon Convertible Share warrants. The total Share Capital after conversion stands at Rs. 19,27,52,380/- divided into 19,27,52,380 fully paid Equity Shares of Re. 1.00 each.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Surya Pharmaceutical Limited has informed the Exchange that the Registered Office of the Company is shifted from the State of Himachal Pradesh to NCT of Delhi w.e.f. December 24, 2010. The new address of Registered Office is as under: Surya Pharmaceutical Limited, # 911, 9th Floor, Surya Kiran Building, 19, K.G.Marg, Connaught Place, New Delhi-110001. However, correspondence address of the Company will remain the same as under: Surya Pharmaceutical Limited, SCO 164-165, Madhya Marg, Sector 9C, Chandigarh - 160009.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of press release dated December 27, 2010, titled "Surya Pharma acquires ActivOn for $22 million".

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on December 24, 2010 have allotted 18,32,52,380 fully paid Equity Shares upon sub-division of Face Value from Rs.10/- each to Rs.1/- each.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on December 24, 2010 has allotted sub-divided equity shares of the Company.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors in their meeting held on December 06, 2010 has fixed December 24, 2010 as record date for the purpose of sub-division of equity shares of the Company.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of the Extra Ordinary General Meeting of the Company held on December 06, 2010

Surya Pharmaceutical Limited has submitted to the Exchange a copy of Notice of the Extra Ordinary General Meeting of the Company to be held on December 06, 2010.

Surya Pharmaceutical Limited has informed the Exchange that an Extra Ordinary General Meeting of the Shareholders has been convened to be held on December 06, 2010 for seeking approval for sub-division of fully paid equity shares of Rs.10/- each to fully paid equity shares of Re.1/- each and consequent alteration in Memorandum & Article of Association of the Company.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 03, 2010 has proposed and recommended sub-division of fully paid equity shares of Rs.10/- each to fully paid equity shares of Re.1/- each and consequent alteration in Memorandum & Articles of Association of the Company.

Surya Pharmaceutical Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors in their meeting held on October 12, 2010 successfully closed the subscription list of issue of GDR of USD 25 million. The issue has been fully subscribed.

Surya Pharmaceutical Limited has informed the Exchange that the Boards of Directors in their meeting held on October 07, 2010 has decided to issue GDR for USD 25 million and the subscription list for the same has been opened. The subscription list is expected to remain open till October 12, 2010. A meeting of the Board of Directors has been convened to be held on October 12, 2010 to decide on the date of closure of the subscription list.

Surya Pharmaceutical Limited has informed the Exchange that the payment of Dividend will be made on or before October 29, 2010.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the shareholders of the Company held on September 30, 2010.

Surya Pharmaceutical Limited has informed the Exchange that the Register of members and share transfer books of the Company shall remain closed from September 29, 2010 to September 30, 2010 for the purpose of Annual Genera Meeting to be held on September 30, 2010 and to determine the Members entitled to receive the final dividend for the year ended March 31, 2010.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at their Meeting held on August 14, 2010 has recommended a dividend @ 15% (Rs.1.50 per share) on Equity Shares of Rs.10/- each.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of Extra Ordinary General Meeting (EOGM) held on June 30, 2010.

Surya Pharmaceutical Limited has informed the Exchange that the Company has started commercial production of its Jammu Plant w.e.f. June 24, 2010. At this plant, the Company have created the capacity to manufacture APIs and sterile products as per USFDA norms for catering to Regulated markets like US and Europe.

Surya Pharmaceutical Limited has informed the Exchange that (1) Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto Rs. 300 crores or equivalent USD from Domestic or International Market by issue of permissible securities for funding its new projects, expansions, diversifications, acquisitions, other business expense and to augment working capital requirements. (2) Subject to the approval of the shareholders and other regulatory approvals, if any, the Board has decided to raise upto 50 million USD through issue of Foreign Curr

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors at its meeting held on May 11, 2010 have considered the following : (1) The Board discussed the future funds requirements of the Company and instead of going ahead with the Rights Issue decided to frame a composite issue and accordingly, the Board constituted a Committee to frame a suitable structure for funds mobilization and seek approval of the shareholders in accordance with Law. (2) Subject to the approval of the shareholders, the Board has decided to increase the Authorized Share Capital from Rs. 50 Crores

Surya Pharmaceutical Limited has informed the Exchange that the Board of Director in their meeting held on April 29, 2010 has allotted 47,00,000 zero coupon convertible share warrants to M/s Futuristics Garments Private Limited in terms of Resolution passed in the Extra Ordinary General Meeting of Shareholders of the Company held on March 14, 2009.

Surya Pharmaceutical Limited has informed the Exchange that " The Board of Directors in their meeting held on 29.04.2010 has allotted 47,00,000 zero coupon convertible share warrants to M/s Futuristics Garments Private Limited in terms of Resolution passed in the Extra Ordinary General Meeting of Shareholders of the Company held on 14.03.2009"

Surya Pharmaceutical Limited has informed the Exchange that a fire broke out in the Company's Banur plant on the night of January 29, 2010. The loss is yet to be ascertained. However, there is no loss of Life or personal injury to any body . Loss of stock/ property is adequately covered by insurance. Further the Company has also informed that the impact of this fire on loss in revenue or production, if any, yet to be ascertained.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 31, 2009 has appointed Dr.H.B.L. Vohra and Mr.S.P.Sharma as Additional Directors on the Board of the Company in order to expand the Board by including Additional Independent Directors.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on September 30, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/suryapharma_proceed_05102009.zip target=NEW> For more details click here.</a>

Surya Pharmaceutical Limited has informed the Exchange that the payment of Dividend will be made on or before October 26, 2009.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors in their meeting held on August 24, 2009 has decided to hold the Annual General Meeting of the Company on September 30, 2009. However, the date of closure of Register of Members and Share Transfer Books for the purpose of Annual General Meeting and declaration of Dividend shall remain the same as informed earlier i.e. September 18, 2009.

Surya Pharmaceutical Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed on September 18, 2009 to determine the Members entitled to receive the final dividend for the year ended March 31, 2009.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on July 31, 2009 has recommended a dividend @ 12% (Rs. 1.20 per share) on Equity Shares of Rs. 10/- each for the financial year 2008-09.

Surya Pharmaceutical Limited has informed the Exchange that Mr. Rajansh Thukral has been appointed as President & Chief Company Secretary of the Company and he shall act as Compliance Officer of the Company in place of Ms. Sugandha Kukreja.

Surya Pharmaceutical Limited has submitted to the Exchange a copy of disclosure under Regulation 8A (4) of SEBI (Substantial Acquisition of Shares and Takeovers) (Amendment) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/SuryaPharma_Pledge_24032009.zip target=NEW> For more details click here.</a>

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of the Extra Ordinary General Meeting of the Company held on March 14, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)<a href=/content/corporate/Surya_EGM_17032009.zip target=NEW> For more details click here.</a>

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the notice of the Extraordinary General Meeting of the members of the Company to be held on March 14, 2009. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Surya_EGM_25022009.zip target=NEW> For more details click here.</a>

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on January 29, 2009. (1) Subject to the approval of the shareholders, the company has resolved to increase the authorised capital of the Company from Rs.26.00 Crores, divided into 2,60,00,000 Equity Shares of Rs.10/- each to Rs.50.00 Crores, divided into 5,00,00,000 Equity Sahres of Rs.10/- each. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announc

Surya Pharmaceutical Limited has informed the Exchange that "12000 Foreign Currency Convertible Bonds (FCCBs) allotted by the Company for the total value of USD 12 million have been redeemed on its due date".

Surya Pharmaceutical Limited has submitted to the Exchange a copy of the proceedings of Annual General Meeting held on September 20, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Surya_ProceedingAGM_29092008.zip target=NEW> For more details click here.</a>

Surya Pharmaceutical Limited has informed the Exchange that the payment of Dividend will be made on or before October 17, 2008.

Surya Pharmaceutical Limited has informed the Exchange that Mr. Rajansh Thukral has resigned from the post of Company Secretary of the Company. However, he shall continue to act as President of the Company. In his place, Ms. Sugandha Kukreja has joined as Company Secretary and she shall act as Compliance Officer of the Company.

Surya Pharmaceutical Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed on September 19, 2008 to determine the Members entitled to receive the final dividend for the year ended March 31, 2008.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors of the Company in their meeting held on July 31, 2008 has recommended a dividend @ 10% (Rs.1.00 per share) on Equity Shares of Rs.10/- each for the financial year 2007-08.

Surya Pharmaceutical Limited has informed the Exchange that "Sh. Sobhagya Mal Jain has resigned from the Directorship of the Company. His resignation has been accepted by the Board of Directors of the Company in their meeting held on October 22, 2007. In his place Sh. Abhishek Arya has been inducted as an Additional Director pursuant to section 260 of the Companies Act, 1956 to fill up the position of Independent Director in compliance with Clause 49 of the Listing Agreement".

Surya Pharmaceutical Limited has informed the Exchange that Transfer Books and Register of Members of the Company shall remain closed on September 14, 2007 for the purpose of Annual General Meeting of the Company to be held on September 15, 2007.

Surya Pharmaceutical Limited has informed the Exchange that the Board of Directors, in their meeting held on October 28,2006, have revised the convertability of Foreign Currency Convertible Bonds issued by the company, in terms of Reset Clause 7.2.4 of the Trust Deed Agreement, whereby effective October 28,2006 onwards, the conversion price of FCCBs shall be Rs. 139.11. Accordingly, the company shall allot 315.9011 fully paid Equity Shares for each FCCB of USD 1000.00. The Authorised Capital of the company is sufficient to accommodate the marginal increase in Equity Shares to be issued upon co

Surya Pharmaceutical Limited has informed the Exchange that the Transfer Books and Register of Members of the Company shall remain closed on September 29, 2006 for the purpose of Annual General Meeting of the Company to be held on September 30, 2006.